Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | ANKRD37 | Human | (-)-demecolcine | decreases expression | EXP | | 6480464 | Demecolcine results in decreased expression of ANKRD37 mRNA | CTD | PMID:23649840 | ANKRD37 | Human | 1,10-phenanthroline | increases expression | EXP | | 6480464 | 1 and 10-phenanthroline results in increased expression of ANKRD37 mRNA | CTD | PMID:19502547 | ANKRD37 | Human | 1,2-dichloroethane | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | ethylene dichloride results in decreased expression of ANKRD37 mRNA | CTD | PMID:28960355 | ANKRD37 | Human | 1,2-dimethylhydrazine | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of ANKRD37 mRNA | CTD | PMID:22206623 | ANKRD37 | Human | 1-chloro-2,4-dinitrobenzene | increases expression | EXP | | 6480464 | Dinitrochlorobenzene results in increased expression of ANKRD37 mRNA | CTD | PMID:25236440 | ANKRD37 | Human | 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of ANKRD37 mRNA | CTD | PMID:21632981 | ANKRD37 | Human | 17beta-estradiol | affects expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Estradiol affects the expression of ANKRD37 mRNA | CTD | PMID:32145629 | ANKRD37 | Human | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | EXP | | 6480464 | Dihydrotestosterone results in increased expression of ANKRD37 mRNA | CTD | PMID:29581250 | ANKRD37 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of ANKRD37 mRNA | CTD | PMID:26377647 | ANKRD37 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ANKRD37 mRNA | CTD | PMID:33387578 | ANKRD37 | Human | 2,4-diaminotoluene | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | 2 and 4-diaminotoluene results in decreased expression of ANKRD37 mRNA | CTD | PMID:20713471 | ANKRD37 | Human | 2-hydroxypropanoic acid | decreases expression | EXP | | 6480464 | Lactic Acid results in decreased expression of ANKRD37 mRNA | CTD | PMID:30851411 | ANKRD37 | Human | 2-palmitoylglycerol | increases expression | EXP | | 6480464 | 2-palmitoylglycerol results in increased expression of ANKRD37 mRNA | CTD | PMID:37199045 | ANKRD37 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ANKRD37 mRNA | CTD | PMID:28628672 | ANKRD37 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Fenretinide results in increased expression of ANKRD37 mRNA | CTD | PMID:28973697 | ANKRD37 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of ANKRD37 mRNA | CTD | PMID:24780913 and PMID:30047161 | ANKRD37 | Human | acrylamide | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Acrylamide results in increased expression of ANKRD37 mRNA | CTD | PMID:30807115 | ANKRD37 | Human | aflatoxin B1 | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Aflatoxin B1 results in decreased expression of ANKRD37 mRNA | CTD | PMID:19770486 | ANKRD37 | Human | amitrole | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Amitrole results in decreased expression of ANKRD37 mRNA | CTD | PMID:30047161 | ANKRD37 | Human | amphetamine | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Amphetamine results in increased expression of ANKRD37 mRNA | CTD | PMID:30779732 | ANKRD37 | Human | arsane | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ANKRD37 mRNA | CTD | PMID:32525701 | ANKRD37 | Human | arsenic atom | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ANKRD37 mRNA | CTD | PMID:32525701 | ANKRD37 | Human | arsenite(3-) | increases methylation | EXP | | 6480464 | arsenite results in increased methylation of ANKRD37 promoter | CTD | PMID:23974009 | ANKRD37 | Human | atrazine | increases expression | EXP | | 6480464 | Atrazine results in increased expression of ANKRD37 mRNA | CTD | PMID:22378314 | ANKRD37 | Human | benzo[a]pyrene | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of ANKRD37 mRNA | CTD | PMID:20713471 | ANKRD37 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of ANKRD37 promoter | CTD | PMID:27901495 | ANKRD37 | Human | benzo[a]pyrene | multiple interactions | ISO | Ankrd37 (Mus musculus) | 6480464 | AHR protein affects the reaction [Benzo(a)pyrene affects the expression of ANKRD37 mRNA] | CTD | PMID:22228805 | ANKRD37 | Human | benzo[a]pyrene diol epoxide I | increases expression | EXP | | 6480464 | 7 more ... | CTD | PMID:19150397 | ANKRD37 | Human | bisphenol A | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of ANKRD37 mRNA | CTD | PMID:25181051 and PMID:32145629 | ANKRD37 | Human | bisphenol A | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of ANKRD37 mRNA | CTD | PMID:35479511 | ANKRD37 | Human | bisphenol A | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of ANKRD37 mRNA | CTD | PMID:34947998 | ANKRD37 | Human | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of ANKRD37 mRNA | CTD | PMID:30903817 | ANKRD37 | Human | bisphenol A | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | bisphenol A results in increased expression of ANKRD37 mRNA | CTD | PMID:25594700 | ANKRD37 | Human | caffeine | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Caffeine results in decreased expression of ANKRD37 mRNA | CTD | PMID:20864626 | ANKRD37 | Human | calcitriol | increases expression | EXP | | 6480464 | Calcitriol results in increased expression of ANKRD37 mRNA | CTD | PMID:21592394 | ANKRD37 | Human | calcitriol | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of ANKRD37 mRNA | CTD | PMID:21592394 | ANKRD37 | Human | carbon nanotube | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Nanotubes and Carbon results in decreased expression of ANKRD37 mRNA | CTD | PMID:25620056 | ANKRD37 | Human | carbon nanotube | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 and PMID:25620056 | ANKRD37 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ANKRD37 gene] | CTD | PMID:28238834 | ANKRD37 | Human | chloroprene | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Chloroprene results in decreased expression of ANKRD37 mRNA | CTD | PMID:23125180 | ANKRD37 | Human | chlorpyrifos | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of ANKRD37 mRNA | CTD | PMID:37019170 | ANKRD37 | Human | clothianidin | decreases expression | EXP | | 6480464 | clothianidin results in decreased expression of ANKRD37 mRNA | CTD | PMID:31626844 | ANKRD37 | Human | cobalt dichloride | multiple interactions | EXP | | 6480464 | zinc chloride inhibits the reaction [cobaltous chloride results in increased expression of ANKRD37 mRNA] | CTD | PMID:22202117 | ANKRD37 | Human | cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of ANKRD37 mRNA | CTD | PMID:19502547 and PMID:22202117 | ANKRD37 | Human | cobalt dichloride | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | cobaltous chloride results in increased expression of ANKRD37 mRNA | CTD | PMID:23814049 and PMID:24386269 | ANKRD37 | Human | cobalt(2+) sulfate | increases expression | EXP | | 6480464 | cobalt sulfate results in increased expression of ANKRD37 mRNA | CTD | PMID:19502547 | ANKRD37 | Human | copper atom | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of ANKRD37 mRNA | CTD | PMID:20971185 | ANKRD37 | Human | copper(0) | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of ANKRD37 mRNA | CTD | PMID:20971185 | ANKRD37 | Human | coumarin 460 | increases expression | EXP | | 6480464 | 4-methyl-7-diethylaminocoumarin results in increased expression of ANKRD37 mRNA | CTD | PMID:19502547 | ANKRD37 | Human | crotonaldehyde | increases expression | EXP | | 6480464 | 2-butenal results in increased expression of ANKRD37 mRNA | CTD | PMID:20471460 | ANKRD37 | Human | curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of ANKRD37 mRNA | CTD | PMID:17198877 | ANKRD37 | Human | cyclosporin A | affects expression | EXP | | 6480464 | Cyclosporine affects the expression of ANKRD37 mRNA | CTD | PMID:20106945 | ANKRD37 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of ANKRD37 mRNA | CTD | PMID:27989131 | ANKRD37 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of ANKRD37 mRNA | CTD | PMID:21632981 and PMID:25562108 | ANKRD37 | Human | cyclosporin A | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Cyclosporine results in decreased expression of ANKRD37 mRNA | CTD | PMID:19770486 | ANKRD37 | Human | deoxynivalenol | decreases expression | EXP | | 6480464 | deoxynivalenol results in decreased expression of ANKRD37 mRNA | CTD | PMID:31863870 | ANKRD37 | Human | dexamethasone | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ANKRD37 mRNA | CTD | PMID:28628672 | ANKRD37 | Human | dibutyl phthalate | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Dibutyl Phthalate results in decreased expression of ANKRD37 mRNA | CTD | PMID:21266533 | ANKRD37 | Human | dioxygen | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Oxygen deficiency results in increased expression of ANKRD37 mRNA | CTD | PMID:20880076 | ANKRD37 | Human | dioxygen | multiple interactions | ISO | Ankrd37 (Mus musculus) | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of ANKRD37 mRNA | CTD | PMID:30529165 | ANKRD37 | Human | dioxygen | increases expression | EXP | | 6480464 | Oxygen deficiency results in increased expression of ANKRD37 mRNA | CTD | PMID:19502547 more ... | ANKRD37 | Human | dioxygen | multiple interactions | EXP | | 6480464 | 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1 more ... | CTD | PMID:24403227 | ANKRD37 | Human | diphenylcyclopropenone | increases expression | EXP | | 6480464 | diphenylcyclopropenone results in increased expression of ANKRD37 mRNA | CTD | PMID:25236440 | ANKRD37 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ANKRD37 | Human | endosulfan | affects expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Endosulfan affects the expression of ANKRD37 mRNA | CTD | PMID:29391264 | ANKRD37 | Human | entinostat | decreases expression | EXP | | 6480464 | entinostat results in decreased expression of ANKRD37 mRNA | CTD | PMID:26272509 | ANKRD37 | Human | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA | CTD | PMID:27188386 | ANKRD37 | Human | ethyl methanesulfonate | decreases expression | EXP | | 6480464 | Ethyl Methanesulfonate results in decreased expression of ANKRD37 mRNA | CTD | PMID:23649840 | ANKRD37 | Human | fluoranthene | multiple interactions | ISO | Ankrd37 (Mus musculus) | 6480464 | [1-methylanthracene co-treated with fluoranthene] results in decreased expression of ANKRD37 mRNA | CTD | PMID:28329830 | ANKRD37 | Human | formaldehyde | increases expression | EXP | | 6480464 | Formaldehyde results in increased expression of ANKRD37 mRNA | CTD | PMID:20655997 and PMID:23416264 | ANKRD37 | Human | formaldehyde | decreases expression | EXP | | 6480464 | Formaldehyde results in decreased expression of ANKRD37 mRNA | CTD | PMID:23649840 | ANKRD37 | Human | indole-3-methanol | affects expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | indole-3-carbinol affects the expression of ANKRD37 mRNA | CTD | PMID:21396975 | ANKRD37 | Human | indometacin | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ANKRD37 mRNA | CTD | PMID:28628672 | ANKRD37 | Human | iron atom | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Iron deficiency results in increased expression of ANKRD37 mRNA | CTD | PMID:16629162 | ANKRD37 | Human | iron atom | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Iron deficiency results in increased expression of ANKRD37 mRNA | CTD | PMID:23776592 | ANKRD37 | Human | iron(0) | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Iron deficiency results in increased expression of ANKRD37 mRNA | CTD | PMID:23776592 | ANKRD37 | Human | iron(0) | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Iron deficiency results in increased expression of ANKRD37 mRNA | CTD | PMID:16629162 | ANKRD37 | Human | leflunomide | decreases expression | EXP | | 6480464 | leflunomide results in decreased expression of ANKRD37 mRNA | CTD | PMID:28988120 | ANKRD37 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | ANKRD37 | Human | lipopolysaccharide | increases expression | EXP | | 6480464 | Lipopolysaccharides results in increased expression of ANKRD37 mRNA | CTD | PMID:35811015 | ANKRD37 | Human | menadione | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Vitamin K 3 results in decreased expression of ANKRD37 mRNA | CTD | PMID:25270620 | ANKRD37 | Human | methimazole | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Methimazole results in decreased expression of ANKRD37 mRNA | CTD | PMID:30047161 | ANKRD37 | Human | methoxyacetic acid | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | methoxyacetic acid results in decreased expression of ANKRD37 mRNA | CTD | PMID:20864626 | ANKRD37 | Human | methyl methanesulfonate | decreases expression | EXP | | 6480464 | Methyl Methanesulfonate results in decreased expression of ANKRD37 mRNA | CTD | PMID:23649840 | ANKRD37 | Human | methylmercury chloride | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | methylmercuric chloride results in decreased expression of ANKRD37 mRNA | CTD | PMID:20864626 | ANKRD37 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of ANKRD37 mRNA | CTD | PMID:23179753 and PMID:27188386 | ANKRD37 | Human | mithramycin | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Plicamycin results in decreased expression of ANKRD37 mRNA | CTD | PMID:23814049 | ANKRD37 | Human | mono(2-ethylhexyl) phthalate | decreases expression | EXP | | 6480464 | mono-(2-ethylhexyl)phthalate results in decreased expression of ANKRD37 mRNA | CTD | PMID:36695872 | ANKRD37 | Human | Monobutylphthalate | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | monobutyl phthalate results in decreased expression of ANKRD37 mRNA | CTD | PMID:20864626 | ANKRD37 | Human | N-methyl-4-phenylpyridinium | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of ANKRD37 mRNA | CTD | PMID:28801915 | ANKRD37 | Human | N-methyl-4-phenylpyridinium | increases methylation | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | 1-Methyl-4-phenylpyridinium results in increased methylation of ANKRD37 gene | CTD | PMID:28801915 | ANKRD37 | Human | nickel dichloride | increases expression | EXP | | 6480464 | nickel chloride results in increased expression of ANKRD37 mRNA | CTD | PMID:21455298 | ANKRD37 | Human | nickel dichloride | affects expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | nickel chloride affects the expression of ANKRD37 mRNA | CTD | PMID:22110744 | ANKRD37 | Human | nitrofen | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | nitrofen results in increased expression of ANKRD37 mRNA | CTD | PMID:26720608 | ANKRD37 | Human | ozone | multiple interactions | ISO | Ankrd37 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of ANKRD37 mRNA | CTD | PMID:34911549 | ANKRD37 | Human | p-chloromercuribenzoic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA | CTD | PMID:27188386 | ANKRD37 | Human | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of ANKRD37 mRNA | CTD | PMID:21420995 | ANKRD37 | Human | perfluorohexanesulfonic acid | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | perfluorohexanesulfonic acid results in increased expression of ANKRD37 mRNA | CTD | PMID:37995155 | ANKRD37 | Human | pioglitazone | multiple interactions | EXP | | 6480464 | [pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA and pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA] | CTD | PMID:20847119 | ANKRD37 | Human | pirinixic acid | multiple interactions | ISO | Ankrd37 (Mus musculus) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ANKRD37 mRNA | CTD | PMID:19710929 | ANKRD37 | Human | pirinixic acid | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of ANKRD37 mRNA | CTD | PMID:23811191 | ANKRD37 | Human | quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of ANKRD37 mRNA | CTD | PMID:21632981 | ANKRD37 | Human | quinolin-8-ol | decreases expression | EXP | | 6480464 | Oxyquinoline results in decreased expression of ANKRD37 mRNA | CTD | PMID:21632981 | ANKRD37 | Human | rac-lactic acid | decreases expression | EXP | | 6480464 | Lactic Acid results in decreased expression of ANKRD37 mRNA | CTD | PMID:30851411 | ANKRD37 | Human | resorcinol | increases expression | EXP | | 6480464 | resorcinol results in increased expression of ANKRD37 mRNA | CTD | PMID:22623647 | ANKRD37 | Human | rotenone | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Rotenone results in decreased expression of ANKRD37 mRNA | CTD | PMID:19013527 | ANKRD37 | Human | rotenone | increases expression | EXP | | 6480464 | Rotenone results in increased expression of ANKRD37 mRNA | CTD | PMID:29955902 | ANKRD37 | Human | S-(1,2-dichlorovinyl)-L-cysteine | decreases expression | EXP | | 6480464 | S-(1 and 2-dichlorovinyl)cysteine results in decreased expression of ANKRD37 mRNA | CTD | PMID:33725128 | ANKRD37 | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | ANKRD37 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ANKRD37 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide analog results in increased expression of ANKRD37 mRNA | CTD | PMID:25895662 | ANKRD37 | Human | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of ANKRD37 mRNA | CTD | PMID:26014281 | ANKRD37 | Human | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of ANKRD37 mRNA | CTD | PMID:26014281 | ANKRD37 | Human | sodium arsenate | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ANKRD37 mRNA | CTD | PMID:32525701 | ANKRD37 | Human | sotorasib | multiple interactions | EXP | | 6480464 | [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANKRD37 mRNA | CTD | PMID:36139627 | ANKRD37 | Human | succimer | multiple interactions | ISO | Ankrd37 (Mus musculus) | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in decreased expression of ANKRD37 mRNA | CTD | PMID:21641980 | ANKRD37 | Human | sulfadimethoxine | decreases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Sulfadimethoxine results in decreased expression of ANKRD37 mRNA | CTD | PMID:30047161 | ANKRD37 | Human | sunitinib | increases expression | EXP | | 6480464 | Sunitinib results in increased expression of ANKRD37 mRNA | CTD | PMID:31533062 | ANKRD37 | Human | tert-butyl hydroperoxide | multiple interactions | EXP | | 6480464 | [pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA more ... | CTD | PMID:20847119 | ANKRD37 | Human | tert-butyl hydroperoxide | increases expression | EXP | | 6480464 | tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA | CTD | PMID:20847119 | ANKRD37 | Human | testosterone | increases expression | EXP | | 6480464 | Testosterone results in increased expression of ANKRD37 mRNA | CTD | PMID:21592394 | ANKRD37 | Human | testosterone | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of ANKRD37 mRNA | CTD | PMID:21592394 | ANKRD37 | Human | thalidomide | decreases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | Thalidomide results in decreased expression of ANKRD37 mRNA | CTD | PMID:26217789 | ANKRD37 | Human | thimerosal | decreases expression | EXP | | 6480464 | Thimerosal results in decreased expression of ANKRD37 mRNA | CTD | PMID:27188386 | ANKRD37 | Human | titanium dioxide | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | titanium dioxide results in increased expression of ANKRD37 mRNA | CTD | PMID:27760801 | ANKRD37 | Human | trametinib | multiple interactions | EXP | | 6480464 | [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANKRD37 mRNA | CTD | PMID:36139627 | ANKRD37 | Human | tributylstannane | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | tributyltin results in increased expression of ANKRD37 mRNA | CTD | PMID:21683754 | ANKRD37 | Human | triptonide | increases expression | ISO | Ankrd37 (Mus musculus) | 6480464 | triptonide results in increased expression of ANKRD37 mRNA | CTD | PMID:33045310 | ANKRD37 | Human | troglitazone | multiple interactions | EXP | | 6480464 | [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA and troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA] | CTD | PMID:20847119 | ANKRD37 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of ANKRD37 mRNA | CTD | PMID:23179753 and PMID:27188386 | ANKRD37 | Human | valproic acid | increases expression | ISO | Ankrd37 (Rattus norvegicus) | 6480464 | Valproic Acid results in increased expression of ANKRD37 mRNA | CTD | PMID:29427782 | ANKRD37 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of ANKRD37 mRNA | CTD | PMID:28001369 | ANKRD37 | Human | vincristine | decreases expression | EXP | | 6480464 | Vincristine results in decreased expression of ANKRD37 mRNA | CTD | PMID:23649840 | ANKRD37 | Human | vorinostat | decreases expression | EXP | | 6480464 | vorinostat results in decreased expression of ANKRD37 mRNA | CTD | PMID:27188386 | ANKRD37 | Human | zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of ANKRD37 mRNA | CTD | PMID:18593933 | ANKRD37 | Human | zinc dichloride | multiple interactions | EXP | | 6480464 | zinc chloride inhibits the reaction [cobaltous chloride results in increased expression of ANKRD37 mRNA] | CTD | PMID:22202117 | ANKRD37 | Human | zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of ANKRD37 mRNA | CTD | PMID:18593933 | |